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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. The plasminogen activator inhibitor-1 4G/5G and tissue plas-
minogen activator Alu-repeat insertion/deletion polymorphisms
might be genetic determinations of increased or decreased of
their plasma activities. The aim of this study was to investigate
the association of plasminogen activator inhibitor-1 4G/5G and
tissue plasminogen activator Alu-repeat I/D polymorphisms with
metabolic syndrome parameters in normal Malaysian subjects and
to assess the impact of these polymorphisms on their plasma
activities and antigens. The genetic polymorphisms were geno-
typed in 130 normal subjects. In addition, the plasma activities
and antigens of plasminogen activator inhibitor-1 and tissue plas-
minogen activator as well as levels of insulin, glucose, and lipid
profile at fasting state were investigated. The subjects with
homozygous 4G/4G showed association with an increased trigly-
ceride (p = 0.007), body mass index (p = 0.01) and diastolic blood
pressure (p = 0.03). In addition, the plasminogen activator inhibitor-
1 4G/5G polymorphism modulates plasma plasminogen activator
inhibitor-1 activity and antigen and tissue plasminogen activator
activity (p = 0.002, 0.014, 0.003) respectively. These results showed
that, the plasminogen activator inhibitor-1 4G/5G polymorphism
is associated with metabolic syndrome parameters, plasminogen
activator inhibitor-1 and tissue plasminogen activator activities in
Malaysian subjects, and may serve to increase the risk of type 2
diabetes and cardiovascular disease in Malaysian subjects.
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Introduction Central obesity, hyperglycaemia, hyperinsulinemia, high trigly-
cerides (TG), low levels of high-density lipoprotein choles-
terol (HDL-c), hypertension and endothelial dysfunction are
well-documented risk factors for type 2 diabetes (T2D), athero-
sclerosis and cardiovascular disease (CVD).(1,2) The constellation
of these metabolic abnormalities known as a metabolic syndrome
(MetS) or insulin resistance syndrome increases the risk of T2D
and CVD. The number of individuals with the MetS has increased
globally during the past two decades, and this increase is
associated with the worldwide epidemic of obesity and diabetes.(3)
High PAI-1 levels have been reported in obese and MetS
subjects.(2,4) Increase in plasma proinsulin, C-peptide and insulin,
have also been associated with high levels of PAI-1.(5)
Plasma PAI-1 is the major physiological inhibitor of endo-
genous fibrinolysis. It inhibits the action of tissue plasminogen
activator (tPA) and urokinase plasminogen activator (uPA), often
leading to fibrin accumulation in basement membranes and
interstitial tissues.(6–8) Elevation in plasma PAI-1 appears to
compromise normal fibrin clearance mechanisms and promotes
thrombosis.
Several SNPs in the PAI-1 gene have been identified,(9) among
which the 4G/5G polymorphism (rs1799889) located in the
promoter region −675 bp upstream from the mRNA synthesis
initiation point has been quite extensively studied. Association of
this polymorphism and variables related to the MetS were,
however, unclear which carriers of the 4G allele being more prone
to obesity and MetS in some studies(9–11) but not in others.(12–14)
Alu repeat I/D polymorphism was found in intron 8 of the tPA
gene.(15) This Alu repeats probably arose early in human evolution,
and a number of populations have been found to be dimorphic
for its presence or absence of repeats.(16) This polymorphism,
however, not significantly correlated with basal endothelial tPA
synthesis.(17)
The PAI-1 4G/5G and tPA polymorphisms and their role in
modulating plasma levels of PAI-1 and tPA activities and antigens
have not been reported in Malaysian subjects. We studied the
association of PAI-1 4G/5G and tPA polymorphisms with MetS
parameters and plasma levels of PAI-1 and tPA activities and
antigens in normal Malaysian subjects.
Materials and Methods
Subjects and data collection. In this study, normal subjects
without diabetes and MetS in the Klang Valley, Kuala Lumpur
were recruited. The study was approved by the Medical Ethics
Committee of University Malaya Medical Centre. Written informed
consent was obtained from each subject. Blood pressure (BP)
measurements were taken from each subject’s right arm in the
seated position by using an Omron IntelliSense Automatic Blood
Pressure Monitor after 10 min of rest in a quiet room in the
morning. Between two and three successive BP readings were
obtained at 5-min intervals and averaged. Body weight and height
were measured and BMI was computed as weight (kg) divided by
height (m2). Waist circumference was measured midway between
the lower rib margin and the superior iliac spine at the end of
gentle expiration in a standing position.
Fasting venous blood (10 ml) was collected from each subject
within a 2 h window (8:00 to 10:00 AM) after 15 min rest, because
of the diurnal variation of plasma PAI-1.(18) The collected blood
immediately taken into five labelled Vacutainer tubes, 0.109 M
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trisodium citrate (for tPA and PAI-1 antigens and PAI-1/tPA
complex analysis), acidified 0.5 M sodium citrate (for tPA and
PAI-1 activities), sodium fluoride (for glucose measurement),
plain (for insulin and lipid profile) and K2 EDTA tubes (for
genetic analysis). The plasma/serum was separated gently within
30 min by using Allerga R X-12R centrifuge (Beckman Coulter.
Inc., Fullerton, CA) for a 15 min at 2,500–3,000 × g at 4°C,
aliquoted into corresponding micro tubes and immediately kept at
−80°C until analysis.
Biochemical analyses. Serum TG, HDL-c and plasma
glucose were measured by an automated analyzer Dimension®
RxL Max® Integrated Chemistry System (Siemens Healthcare
Diagnostics Inc., Deerfield, IL). Insulin was measured by ADVIA
Centaur assay XP Immunoassay System (Siemens Healthcare
Diagnostics Inc., Deerfield, IL). Investigations were done at
Clinical Diagnostic Laboratory of the University Malaya Medical
Centre (UMMC), Kuala Lumpur. Insulin resistance (IR) and
Insulin sensitivity (IS) were calculated using the Homeostasis
Model Assessment (HOMA2) Calculator v2.2 which is available
from Oxford Centre for Diabetes, Endocrinology and Metabolism.
Plasma PAI-1 antigen was measured by TintElize® PAI-1 antigen
ELISA test from Biopool (Trinity Biotech Inc. Jamestown, NY).
PAI-1 activity, tPA activity and antigen and tPA/PAI-1complex
were measured by PAI-1 activity, tPA activity, tPA total antigen,
tPA/PAI-1 complex human assays respectively, (Molecular
Innovations, Inc. Peary Court, Novi, MI) according to the manu-
facturer’s instructions. Plates were read at 450 nm except the
PAI-1 antigen plate which was at 490 nm using a microplate
reader (BioRad, Calabasas, CA).
Genetic analysis
DNA extraction. Leukocyte genomic DNA was extracted from
whole EDTA blood using a commercially Wizard® Genomic DNA
Purification Kit (Promega Corporation, Madison, WI) according
to the manufacturer’s instructions.
Genotyping of PAI-1 polymorphisms. Allele specific PCR was
used to detect the genotypes of PAI-1 4G/5G. Two specific for-
ward allele primers (5G, 5'-GAGTCTGGACACGTGGGGG-3' at
3' end is G and 4G, 5'-GAGTCTGGACACGTGGGGA-3 at 3' end
the 5th G was replaced by A as matching the subsequent sequence)
were designed to detect this SNP. An internal control is necessary
to ensure that there was PCR amplification in each reaction.
Therefore, common forward (upstream of allele specific primers
5'-TGGTCCCGTTCAGCCACCA-3') and reverse primers (down-
stream of allele specific primers 5'-ATGCAGCCAGCCAC-
GTGAT-3') were used as PCR amplification controls with each
PCR reaction. The reverse primer also is a reverse primer for the
two allele specific primers.
Amplification reactions of PAI-1 were performed in two sepa-
rated PCR reactions using 20 μl volume of PCR contained 50 ng
of genomic DNA, 5 pmol of allele specific primer 5G or 4G,
1.2 pmol of forward primer, 5 pmol of reverse primer, 1.5 mM
MgCl2, 1X PCR buffer, 1X Q-Solution, 100 μM dNTPs and 0.5
unit of HotStarTaq Plus DNA Polymerase (Qiagen, Valencia, CA).
DNA was denaturated at 94°C for 5 min, followed by 25 cycles of
denaturation at 94°C for 1 min, annealing at 63°C for 45 s, and
extension at 70°C for 75 s, with a final extension step for 5 min
at 72°C. The PCR products were run by electrophoresis in a 7%
polyacrylamide gel (PAGE) and stained with ethidium bromide
(EtBr). Band was visualized by the gel document system (Infinity
3026, Vilber Lourmat, Marnela Valled, France). Some of the
PCR products were sent for sequencing Bioneer Corporation
(Daedeok-gu, Daejeon, South Korea) to confirm the obtained
results.
Genotyping of tPA polymorphisms. An I/D polymorphism re-
sulting from the presence or absence of Alu repeats in intron 8 of
the tPA gene was assessed by PCR using the following primers.(19)
Sense primer: 5'-GTGAAAAGCAAGGTCTACCAG-3' and non-
sense primer: 5'-GACACCGAGTTCATCTTGA-C-3'. PCR reac-
tion was performed in a 20 μl volume with 10 pmol of each primer,
200 μM dNTP, 3 mM MgCl2, 1X PCR buffer, 1X Q-Solution, 1
unit HotStarTaq Plus DNA polymerase and 50 ng genomic DNA.
The samples were initially denaturated at 94°C for 5 min before
subjected to 30 cycles consisting of 1 min at 94°C (denaturation),
1 min at 60°C (annealing) and 75 s at 71°C (extension) in a
thermal cycler followed by final extension at 72°C for 10 min. 9 μl
of each product were electrophoresed on a 1% agarose gel, then
stain by EtBr and visualized by the gel document system. To
confirm the results, some of PCR products were sent to Bioneer
Corporation (Daedeok-gu, Daejeon, South Korea) for sequencing.
Statistical analyses. Calculator to determine whether
observed genotype frequencies are consistent with Hardy-
Weinberg equilibrium (HW) was done by the method of Court
(2005, 2008). The other statistical analyses were done by SPSS
11.5 (Social Package of Statistical Science) computer program by
LEAD Technologies; Inc., Chicago, IL). The missing data were
listwise deleted (when any of the variables were missing, the
entire observation was omitted from the analysis). The BMI,
waist, systolic blood pressure (SBP) and diastolic blood pressure
(DBP), TG, HDL-c, FBS, insulin, IS, IR, tPA antigen and activity,
PAI-1 antigen and activity, and tPA/PAI-1 complex were log
transformed because they were not normally distributed. These
parameters means and 95% confidence intervals were transformed
back and reported as geometric means. The association of genetic
Polymorphisms of PAI-1 and tPA with metabolic syndrome
parameters; (BMI, waist, SBP, DBP, TG, HDL-c, FBS, insulin,
IS and IR) and fibrinolytic PAI-1 and tPA activities and antigens,
and tPA/PAI-1 complex (dependent variables) were analysed by
univariate analyses (general linear model) adjusted for age,
gender and race as covariates. The difference between means was
considered significant if the p value <0.05.
Results
Of five hundred normal respondents, 190 were recruited for the
study. After biochemical tests and application of IDF criteria for
MetS diagnosis,(20) 130 of those were revealed as normal without
overt diabetes or MetS. The biochemical and clinical parameters
of the subjects are shown in Table 1. In general, univariate tests
Table 1. Biochemical and clinical parameters among subjects
The result presented as mean ± SD. Number of subjects = 130.
Parameters Value
Gender % Male/Female 34.6/65.4
Races % Malay 52.3
Chinese 33.8
Indian 13.8
Age (yrs) 49.1 ± 12.57
Body mass index (kg/m2)2 3 . 0 ± 3.76
Waist circumference (cm) 79.9 ± 11.01
Diastolic blood pressure (mmHg) 80.4 ± 8.97
Systolic blood pressure (mmHg) 131.8 ± 18.30
Triglyceride (mmol/l) 1.1 ± 0.56
High density lipoprotein (mmol/l) 1.6 ± 0.37
Low density lipoprotein (mmol/l) 3.2 ± 0.88
Fasting blood glucose (mmol/l) 5.0 ± 0.51
Insulin (pmol/l) 53.3 ± 35.55
Insulin resistance (IR) 1.0 ± 0.66
PAI-1 activity (IU/ml) 15.5 ± 8.90
PAI-1 antigen (ng/ml) 34.8 ± 18.96
tPA activity (U/ml) 3.3 ± 2.95
tPA antigen (ng/ml) 4.4 ± 2.87
tPA/PAI-1 complex (ng/ml) 5.0 ± 3.05doi: 10.3164/jcbn.11-48
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showed that the PAI-1 4G/5G variant was associated with BMI
(p = 0.032) and TG (p = 0.026) but not-significantly associated
with other MetS parameters (Table 2). On the other hand, the
Pairwise Comparisons showed that the subjects carrying homozy-
gous 4G/4G were had higher BMI (p = 0.01), DBP (p = 0.03) and
TG (p = 0.007) than those with homozygous 5G/5G genotype.
Furthermore, the DBP, TC and LDL-c were higher in the subjects
with heterozygous 4G/5G compared to those carrying the 5G/5G
genotype (p = 0.008, 0.047, 0.03 respectively). Univariate analyses
showed that the tPA polymorphism was not associated with MetS
parameters with p value >0.05 (Table 3).
Univariate test, showed that, the PAI-1 4G/5G polymorphism
Table 2. Association of PAI-1 polymorphism with metabolic syndrome parameters among subjects
The result presented as geometric mean and 95% confidence interval of the mean adjusted for age, gender and race as covariates which evaluated
by univariate (General Linear Model). Number of subjects = 130.
Metabolic syndrome parameter
PAI-1 polymorphism
5G/5G 
n (37)
4G/5G 
n (63)
4G/4G 
n (30)
Univariat 
p value
4G/4G vs 5G/5G 
p value
4G/5G vs 5G/5G 
p value
Body mass index (kg/m2) 21.3 
(20.4–22.3)
22.4 
(21.7–23.2)
23.2 
(22.1–24.4) 0.032 0.01 0.08
Waist circumference (cm) 77.1 
(74.8–79.4)
78.4 
(76.7–80.3)
78.0 
(75.3–80.8) 0.66 0.61 0.34
Diastolic blood pressure (mmHg) 77.5 
(75.3–79.7)
80.4 
(78.7–82.2)
81.2 
(78.6–83.9) 0.056 0.03 0.008
Systolic blood pressure (mmHg) 127 
(123–132)
129 
(125–132)
133 
(128–138) 0.23 0.096 0.62
Triglyceride (mmol/l) 0.92 
(0.80–1.03)
1.04 
(0.95–1.14)
1.17 
(1.03–1.33) 0.026 0.007 0.099
T-cholesterol (mmol/l) 4.97 
(4.72–5.24)
5.32 
(5.11–5.54)
5.21 
(4.90–5.53) 0.14 0.26 0.047
HDL-cholesterol (mmol/l) 1.62 
(1.52–1.72)
1.52 
(1.46–1.59)
1.51 
(1.41–1.61) 0.21 0.12 0.13
LDL-cholesterol (mmol/l) 2.90 
(2.66–3.16)
3.27 
(3.07–3.49)
3.00 
(2.71–3.30) 0.07 0.64 0.03
Fasting blood sugar (mmol/l) 5.01 
(4.9–5.15)
4.97 
(4.87–5.08)
4.93 
(4.77–5.09 0.75 0.45 0.69
Insulin (pmol/l) 39.9 
(34.3–46.4)
43.7 
(38.8–49.1)
46.9 
(39.3–55.8) 0.38 0.17 0.35
Insulin resistance 0.78 
(0.66–0.91)
0.86 
(0.76–0.96)
0.89 
(0.74–1.06) 0.5 0.27 0.37
Table 3. Association of tPA Polymorphism with metabolic syndrome parameters among subjects
The result presented as geometric mean and 95% confidence interval of the mean adjusted for age, gender and race as covariates which evaluated
by univariate (General Linear Model). Number of subjects = 130.
Metabolic syndrome parameter
tPA polymorphism
D/D 
n (36)
I/D 
n (63)
I/I 
n (30)
Univariate 
p value
I/I vs D/D 
p value
I/D vs D/D 
p value
Body mass index (kg/m2) 22.1 
(21.1–23.2)
22.4 
(21.7–23.2)
22.0 
(21.0–23.0) 0.76 0.84 0.65
Waist circumference (cm) 77.4 
(75.0–79.8)
77.9 
(76.2–79.7)
78.4 
(76.0–80.9) 0.83 0.45 0.72
Diastolic blood pressure (mmHg) 79.7 
(77.3–82.2)
79.0 
(77.2–80.9)
80.6 
(78.0–83.3) 0.63 0.61 0.68
Systolic blood pressure (mmHg) 133 
(128–138)
129 
(126–132)
128 
(124–133) 0.32 0.19 0.17
Triglyceride (mmol/l) 0.95 
(0.83–1.08)
1.04 
(0.95–1.14)
1.12 
(0.98–1.27) 0.2 0.07 0.25
T-cholesterol (mmol/l) 5.07 
(4.81–5.34)
5.30 
(5.09–5.51)
5.32 
(5.00–5.66) 0.35 0.9 0.19
HDL-cholesterol (mmol/l) 1.56 
(1.46–1.66)
1.54 
(1.47–1.61)
1.52 
(1.42–1.63) 0.86 0.59 0.69
LDL-cholesterol (mmol/l) 3.02 
(2.77–3.28)
3.18 
(2.98–3.39)
3.17 
(2.87–3.50) 0.58 0.43 0.32
Fasting blood sugar (mmol/l) 4.96 
(4.82–5.10)
4.98 
(4.88–5.08)
5.02 
(4.87–5.17) 0.84 0.55 0.8
Insulin (pmol/l) 39.5 
(33.8–46.0)
45.2 
(40.2–50.7)
42.2 
(35.6–50.0) 0.39 0.56 0.17
Insulin resistance 0.78 
(0.66–0.92)
0.89 
(0.79–1.00)
0.83 
(0.69–0.98) 0.45 0.66 0.22 J. Clin. Biochem. Nutr. | May 2012 | vol. 50 | no. 3 | 187
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was strongly associated with PAI-1 activity and antigen and tPA
activity (p = 0.002, 0.014, 0.003 respectively) (Table 4). On the
other hand, the tPA Alu-repeat I/D polymorphism was associated
with tPA/PAI-1 complex (p = 0.04) and weakly associated with the
tPA activity (p = 0.06). The tPA Alu-repeat I/D polymorphism was
not associated with PAI-1 and tPA antigens or PAI-1 activity
(Table 5).
Pairwise comparison indicated that the PAI-1 activity and
antigen was higher in subjects having homozygous 4G/4G (p =
0.03, 0.014 respectively), or heterozygous 4G/5G (p =4 . 6× 10−4,
0.007 respectively), than those carrying homozygous 5G/5G. In
contrast, the tPA activity was lower in subjects having homozy-
gous 4G/4G or heterozygous 4G/5G of PAI-1 polymorphism than
those with homozygous 5G/5G (p = 0.12, 0.04).
Univariate analysis showed that the homozygous I/I and D/D as
well as homozygous D/D and heterozygous I/D of tPA poly-
morphism were not associated with fibrinolytic PAI-1 and tPA
activities and antigens and the levels of tPA/PAI-1 complex
(Table 5).
Discussion
The association of PAI-1 4G/5G and tPA Alu-repeat I/D poly-
morphisms with MetS parameters was assessed in normal
Malaysian subjects. The impact of these polymorphisms on PAI-1
and tPA activities and levels were also evaluated. The homozy-
gous PAI-1 4G/4G genotype showed significant association with
MetS parameters; plasma TG, BMI and DBP. Hoffstedt et al.(13)
had linked this variant with obesity. However, the mechanism by
which polymorphisms in the PAI-1 promoter affect MetS para-
meters is not known.
The risk of MetS is notably higher in 4G carriers since it is
associated with elevated plasma PAI-1 and reduced tPA activities.
This finding is in agreement with previous studies reporting a
similar association between the PAI-1 4G variant and increased
risk of T2D and MetS in 1272 healthy employees in southern Italy
and 210 Caucasian subjects,(21,22) and high levels of fibrinolytic
PAI-1 and tPA.(23) The PAI-1 5G allele contains an additional
binding site for a DNA-binding protein that is thought to play a
pivotal role as a repressor during transcription.(24,25) The binding
of the transcriptional repressor may decrease the binding of
transcriptional activator(26) and this may explain why PAI-1 4G
alleles have higher PAI-1 activity. A deletion allele (4G) in the
PAI-1 promoter raises PAI-I activity.(27,28) The PAI-1 activity and
antigen are expected to be higher in homozygous 4G/4G than
heterozygous 4G/5G individuals. However, there are no signifi-
cant differences in both PAI-1 activity and antigen between 4G/5G
and 4G/4G (p = 0.33, 0.88 respectively). This may be interpreted
to mean PAI-1 mono-allelic expression in 4G/5G individuals.
Allelic variation in gene expression is common in the human
genome.(29–31) In addition, genomic and epigenetic changes in
PAI-1 may also affect overall PAI-1 expression.
Sternlicht et al.(32) summarized the published data about levels
and activity of PAI-1 among different populations carrying the
PAI-1 5G/5G, 4G/5G and 4G/4G genotypes. The results showed a
discrepancy in the levels and activity of PAI-1 among different
Table 4. Association of PAI-1 polymorphisms with their plasma activities and antigens and tPA/PAI-1 complex among subjects
The result presented as geometric mean and 95% confidence interval of the mean adjusted for age, gender and race as covariates which evaluated
by univariate (General Linear Model). Number of subjects = 130.
Parameters
PAI-1 polymorphism
5G/5G 
n (37)
4G/5G 
n (63)
4G/4G 
n (30)
Univariate 
p value
4G/4G vs 5G/5G 
p value
4G/5G vs 5G/5G 
p value
PAI-1 activity (IU/ml) 9.93 
(8.15–12.1)
13.9 
(12.9–17.3)
13.6 
(11.0–16.8) 0.002 0.03 4.6 × 10−4
PAI-1 antigen (ng/ml) 25.8 
(22.2–30.1)
33.6 
(30.0–37.6)
34.1 
(29.0–40.1) 0.014 0.014 0.007
tPA activity (U/ml) 2.12 
(1.57–2.80)
3.02 
(2.48–3.65)
1.58 
(1.08–2.20) 0.003 0.12 0.04
tPA antigen (ng/ml) 3.49 
(2.77–4.36)
3.51 
(2.95–4.15)
4.41 
(3.42–5.62) 0.29 0.17 0.97
tPA/PAI–1 complex (ng/ml) 2.62 
(1.63–3.98)
2.31 
(1.60–3.21)
3.39 
(2.06–5.31) 0.44 0.43 0.66
Table 5. Association of tPA polymorphisms with their plasma activities and antigens and tPA/PAI-1 complex among subjects
The result presented as geometric mean and 95% confidence interval of the mean adjusted for age, gender and race as covariates which evaluated
by univariate (General Linear Model). Number of subjects = 130.
Parameters
tPA polymorphism
D/D 
n (36)
I/D 
n (63)
I/I 
n (30)
Univariate 
p value
I/I vs D/D 
p value
I/D vs D/D 
p value
PAI-1 activity (IU/ml) 12.5 
(10.3–15.1)
14.7 
(12.6–17.1)
14.6 
(11.7–18.3) 0.33 0.26 0.16
PAI-1 antigen (ng/ml) 34.5 
(29.3–40.4)
32.3 
(28.4–36.8)
28.3 
(23.9–33.6) 0.25 0.11 0.57
tPA activity (U/ml) 2.60 
(1.94–3.40)
1.97 
(1.54–2.46)
3.03 
(2.24–4.02) 0.06 0.45 0.14
tPA antigen (ng/ml) 3.93 
(3.11–4.92)
3.74 
(3.10–4.48)
3.33 
(2.54–4.28) 0.5 0.3 0.96
tPA/PAI-1 complex (ng/ml) 2.44 
(1.50–3.74)
3.46 
(2.50–4.67)
1.59 
(0.84–2.65) 0.04 0.23 0.21doi: 10.3164/jcbn.11-48
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populations. Our results were similar to that found in Chinese’s
men.(33)
Plasma levels of PAI-1 are determined by both environmental
and genetic factors. Although the regulation of PAI-1 is multi-
factorial in nature, the influence of genetic factors cannot be
excluded. There has been a growing interest in the influence of
genetic variation within the PAI-1 gene on plasma PAI-1 concen-
trations,(34,35) and the difference in PAI-1 levels between 4G and
5G are more apparent in the presence of environmental and/or
disease factors, which stimulate PAI-1 expression.(36) However,
the interactions of genetic and environmental determinants on
PAI-1 expression are not fully understood.
MetS is a multifactorial and polygenic entity in which the
fibrinolytic system has been shown to be implicated. It has been
reported that there was a clear trend toward increasing PAI-1
activity with increased insulin resistance, waist circumference,
BMI, and decreased HDL-c.(1) Studies on the genetic input on
body fat distribution has demonstrated that 56% of the variance in
abdominal visceral fat mass was due to genetic factors.(37) High
PAI-1 activity has been reported to be associated with cardio-
vascular events.(38,39) Meta analysis has shown that PAI-1 4G/5G
polymorphism contributed to cardiovascular, ischemic stroke and
venous thromboembolism risk(40–42) and 20% increased risk of
myocardial infarction.(43) However, treatment by the PAI-1 inhibi-
tors improved histological remodeling of myocardium and arteries
with suppression of inflammation and thrombus format.(44)
The association of tPA I/D polymorphism with MetS was
not-significant. This is in agreement with previous studies
demonstrating a lack of association between the tPA gene and
hypertension, a MetS parameter in Chinese Han(45) and Korean
populations.(19) Hence, this variation in the tPA gene may not be
appropriate for prediction of MetS.
Conclusion
The PAI-1 4G/5G polymorphism is associated with MetS
parameters; BMI, TG, and blood pressure which may increase
the risk of MetS and T2D and CVD in Malaysian subjects. The
impaired fibrinolytic activity of PAI-1 and tPA is well known risk
factor for T2D and CVD and this association might indicate
modulation by PAI-1 4G/5G polymorphism.
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